Full Prescribing Information Important Safety Information
CLOSE
SAVINGS & SUPPORT
MENU

THIS WEBSITE IS INTENDED FOR US HEALTHCARE PROFESSIONALS ONLY.

I certify that I am a healthcare professional in the US.

NO

GET CONNECTED

For the treatment of moderate to severe Vasomotor Symptoms (VMS)—commonly referred to as hot flashes and night sweats—due to menopause1,2

Woman and doctor holding VEOZAH™ (fezolinetant) logo fire extinguisher

HELPyourPATIENTS
ACCESS VEOZAH

VEOZAH® (fezolinetant) Savings Card

For eligible patients with commercial prescription insurance

Patients may pay $0 for the first monthly prescription and may pay as little as $30 per monthly refill.*
If a prior authorization is required, it is important to submit your patient’s required insurance paperwork, such as Prior Authorization Form or Letter of Medical Necessity (if applicable) as soon as possible to ensure patients can use the savings card and to help avoid potential delays.
Guide your patients through enrollment. Tell them to visit VEOZAHsavings.com or skip straight to downloading a unique savings card here.
DOWNLOAD SAVINGS CARD
Link icon copied for resource download Link icon to copy resource download COPY LINKLINK COPIED

Terms & Conditions

By enrolling in the VEOZAH Savings Program ("Program"), the patient acknowledges that they currently meet the eligibility criteria and will comply with the following terms and conditions: The Program is for eligible patients with commercial prescription insurance and is good for use only with a valid prescription for VEOZAH™ (fezolinetant) at the time the prescription is dispensed by the pharmacy. The Program has an annual maximum copay assistance limit of up to $4,000 per calendar year. After the annual maximum on copay assistance is reached, patient will be responsible for the remaining monthly out-of-pocket costs for VEOZAH. Astellas may reduce or discontinue the copay assistance available under the Program if it determines an enrolled patient does not have an approved claim for VEOZAH. Unless prohibited by law, Astellas may reduce the total copay assistance available under the Program to a maximum of $1,250 for two months (i.e., two 28–31-day fills) if it determines a VEOZAH claim for an enrolled patient is not approved by their commercial health plan.The Program is not valid for patients whose prescription claims are reimbursed, in whole or in part, by any state or federal government program, including, but not limited to, Medicaid, Medicare, Medigap, Department of Defense (DoD), Veterans Affairs (VA), TRICARE, Puerto Rico Government Insurance, or any state patient or pharmaceutical assistance program. Patients who move from commercial insurance to federal or state prescription health insurance will no longer be eligible, and agree to notify the Program of any such change. Patients agree not to seek reimbursement from any health insurance or third party for all or any part of the benefit received by the patient through the Program. This offer is not conditioned on any past, present, or future purchase of VEOZAH. This offer is not transferable, has no cash value, and cannot be combined with any other offer, free trial, prescription savings card, or discount (including any program offered by a third party payer or pharmacy benefit manager, or an agent of either, that adjusts patient cost-sharing obligations, through arrangements that may be referred to as “accumulator” or “maximizer” programs). The full value of the Program benefits is intended to pass entirely to the eligible patient. No other individual or entity (including, without limitation, third party payers, pharmacy benefit managers, or the agents of either) is entitled to receive any benefit, discount or other amount in connection with this Program. This offer is not health insurance and is only valid for patients in the 50 United States, Washington DC, and Puerto Rico. This offer is not valid for cash paying patients. This Program is void where prohibited by law. No membership fees. It is illegal to sell, purchase, trade, counterfeit, duplicate, or reproduce, or offer to sell, purchase, trade, counterfeit, duplicate or reproduce the card. This offer will be accepted only at participating pharmacies. Certain rules and restrictions apply. Astellas reserves the right to revoke, rescind, or amend this offer without notice for any reason (including to ensure that the offer is utilized solely for the patient's benefit).

VEOZAH® (fezolinetant) Savings Card
*Eligibility requirements and terms and conditions apply.
  • A patient must have a valid commercial prescription for VEOZAH, meet the eligibility requirements, and present the VEOZAH Savings Card to their preferred pharmacy
  • The program has an annual maximum copay assistance limit of up to $4,000 per calendar year. Unless prohibited by law, Astellas may reduce the total copay assistance available under the program to a maximum of $1,250 for two months (i.e., two 28–31-day fills) if it determines a VEOZAH claim for an enrolled patient is not approved by their commercial health plan
  • There are no income requirements
  • The program is not valid for patients whose prescription claims are reimbursed, in whole or in part, by any state or federal government program
  • Offer is not health insurance and is void where prohibited by law
  • Astellas reserves the right to revoke, rescind, or amend this offer at any time

VEOZAH Support Solutions can provide access support to your:

Shield Icon

Commercially insured patients 

Address prescription coverage questions

Shield

Patients with Medicare, Medicaid, or other government insurance

Shield Icon-x

Patients without prescription insurance

The Astellas Patient Assistance Program* provides VEOZAH at no cost to uninsured patients who meet certain requirements

VEOZAHSUPPORTSOLUTIONS.COM

*Subject to eligibility restrictions. Program terms and conditions apply. Void where prohibited by law.

Woman and doctor looking at iPad
RESOURCES

Resources for both you and your patients

Download patient materials, such as the doctor discussion guide.

Resources for both you and your patients

Download patient materials, such as the doctor discussion guide.

Link icon copied for resource download Link icon to copy resource download COPY LINKLINK COPIED
COPY LINKLINK COPIED
Download Link
Patient resources

Find information regarding completing a prior authorization, including checklists and a sample letter of medical necessity. Additionally, you can refer to the list of relevant ICD-10-CM codes.

PRIOR AUTHORIZATION RESOURCES

ICD-10-CM=International Classification of Diseases-10th Revision-Clinical Modification.

~6 of 10

commercially insured patients have access to VEOZAH*

SEE COVERAGE DETAILS

*Data are based on current coverage rates of 63% commercial covered lives as of April 15, 2025 and are not inclusive of Health Exchange. Coverage includes unrestricted and coverage subject to PA and/or step edit.

FORMULARY STATUS DOES NOT IMPLY SAFETY OR EFFICACY OF ANY PRODUCT. NO COMPARISONS SHOULD BE MADE.

PA=prior authorization.

CONTACT YOUR ASTELLAS REPRESENTATIVE

Request a sales representative who can connect you with the appropriate Astellas Account Manager to help address your specific questions.

CALL VEOZAH SUPPORT SOLUTIONS TO SPEAK TO A PATIENT CARE COORDINATOR

Phone: 1-866-239-1637 | Monday–Friday, 8:00 AM–8:00 PM ET

GO ONLINE

Visit VEOZAHSupportSolutions.com.

IMPORTANT SAFETY INFORMATION

INDICATIONS AND USAGE

EXPAND COLLAPSE

IMPORTANT SAFETY INFORMATION

INDICATIONS AND USAGE

WARNING: RISKS OF HEPATOTOXICITY

Hepatotoxicity has occurred with the use of VEOZAH in the postmarketing setting.

  • Perform hepatic laboratory tests prior to initiation of treatment to evaluate for hepatic function and injury. Do not start VEOZAH if either aminotransferase is ≥ 2x the upper limit of normal (ULN) or if the total bilirubin is ≥ 2x ULN for the evaluating laboratory.
  • Perform follow-up hepatic laboratory testing monthly for the first 3 months, at 6 months, and 9 months of treatment.
  • Advise patients to discontinue VEOZAH immediately and seek medical attention including hepatic laboratory tests if they experience signs or symptoms that may suggest liver injury (new onset fatigue, decreased appetite, nausea, vomiting, pruritus, jaundice, pale feces, dark urine, or abdominal pain).
  • Discontinue VEOZAH if transaminase elevations are > 5x ULN, or if transaminase elevations are > 3x ULN and the total bilirubin level is > 2x ULN.
  • If transaminase elevations > 3x ULN occur, perform more frequent follow-up hepatic laboratory tests until resolution.

VEOZAH™ (fezolinetant) is a neurokinin 3 (NK3) receptor antagonist indicated for the treatment of moderate to severe vasomotor symptoms due to menopause.

CONTRAINDICATIONS

VEOZAH is contraindicated in women with any of the following:

  1. Known cirrhosis
  2. Severe renal impairment or end-stage renal disease
  3. Concomitant use with CYP1A2 inhibitors

WARNING: RISKS OF HEPATOTOXICITY

Hepatotoxicity has occurred with the use of VEOZAH in the postmarketing setting.

  • Perform hepatic laboratory tests prior to initiation of treatment to evaluate for hepatic function and injury. Do not start VEOZAH if either aminotransferase is ≥ 2x the upper limit of normal (ULN) or if the total bilirubin is ≥ 2x ULN for the evaluating laboratory.
  • Perform follow-up hepatic laboratory testing monthly for the first 3 months, at 6 months, and 9 months of treatment.
  • Advise patients to discontinue VEOZAH immediately and seek medical attention including hepatic laboratory tests if they experience signs or symptoms that may suggest liver injury (new onset fatigue, decreased appetite, nausea, vomiting, pruritus, jaundice, pale feces, dark urine, or abdominal pain).
  • Discontinue VEOZAH if transaminase elevations are > 5x ULN, or if transaminase elevations are > 3x ULN and the total bilirubin level is > 2x ULN.
  • If transaminase elevations > 3x ULN occur, perform more frequent follow-up hepatic laboratory tests until resolution.
INDICATIONS AND USAGE

VEOZAH™ (fezolinetant) is a neurokinin 3 (NK3) receptor antagonist indicated for the treatment of moderate to severe vasomotor symptoms due to menopause.

CONTRAINDICATIONS

VEOZAH is contraindicated in women with any of the following:

  1. Known cirrhosis
  2. Severe renal impairment or end-stage renal disease
  3. Concomitant use with CYP1A2 inhibitors

WARNINGS AND PRECAUTIONS

Hepatotoxicity

In 3 clinical trials, elevations in serum transaminase [alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST)] levels > 3x ULN occurred in 2.3% of women receiving VEOZAH and 0.9% of women receiving placebo. No elevations in serum total bilirubin (> 2x ULN) occurred. Women with ALT or AST elevations were generally asymptomatic. Transaminase levels returned to pretreatment levels (or close to these) without sequelae with dose continuation, and upon dose interruption, or discontinuation. Women with cirrhosis were not studied.

In the postmarketing setting, cases of drug-induced liver injury with elevations of ALT, AST, alkaline phosphatase (ALP), and total bilirubin occurred within 40 days of starting VEOZAH. Patients reported a general sense of feeling unwell and symptoms of fatigue, nausea, pruritus, jaundice, pale feces, and dark urine. The patients’ signs and symptoms gradually resolved after discontinuation of VEOZAH.

Perform baseline hepatic laboratory tests to evaluate for hepatic function and injury [including serum ALT, serum AST, serum ALP, and serum bilirubin (total and direct)] prior to VEOZAH initiation. Do not start VEOZAH if ALT or AST is ≥ 2x ULN or if the total bilirubin is ≥ 2x ULN for the evaluating laboratory.

Perform follow-up hepatic laboratory tests monthly for the first 3 months, at 6 months, and 9 months after initiation of therapy.

See BOXED WARNING for full hepatic laboratory testing protocol and discontinuation criteria. Exclude alternative causes of hepatic laboratory test elevations.

ADVERSE REACTIONS

The most common adverse reactions with VEOZAH ≥ 2% and > placebo (VEOZAH % vs. placebo %) are: abdominal pain (4.3% vs. 2.1%), diarrhea (3.9% vs. 2.6%), insomnia (3.9% vs. 1.8%), back pain (3.0% vs. 2.1%), hot flush (2.5% vs. 1.6%), and hepatic transaminase elevation (2.3% vs. 0.8%).

Please click here for full Prescribing Information, including BOXED WARNING, for VEOZAH (fezolinetant).

REFERENCES: 1. Veozah. Package insert. Northbrook, IL: Astellas Pharma US, Inc; 2024. 2. Thurston RC. Vasomotor symptoms. In: Crandall CJ, Bachman GA, Faubion SS, et al., eds. Menopause Practice: A Clinician’s Guide. 6th ed. Pepper Pike, OH: The North American Menopause Society, 2019:43-55.

IMPORTANT SAFETY INFORMATION

INDICATIONS AND USAGE

EXPAND COLLAPSE

IMPORTANT SAFETY INFORMATION

INDICATIONS AND USAGE

CONTRAINDICATIONS

VEOZAH is contraindicated in women with any of the following:

  1. Known cirrhosis
  2. Severe renal impairment or end-stage renal disease
  3. Concomitant use with CYP1A2 inhibitors

VEOZAH® (fezolinetant) is a neurokinin 3 (NK3) receptor antagonist indicated for the treatment of moderate to severe vasomotor symptoms due to menopause.

CONTRAINDICATIONS

VEOZAH is contraindicated in women with any of the following:

  1. Known cirrhosis
  2. Severe renal impairment or end-stage renal disease
  3. Concomitant use with CYP1A2 inhibitors
INDICATIONS AND USAGE

VEOZAH® (fezolinetant) is a neurokinin 3 (NK3) receptor antagonist indicated for the treatment of moderate to severe vasomotor symptoms due to menopause.

WARNINGS AND PRECAUTIONS

Hepatic Transaminase Elevation

Elevations in serum transaminase [alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST)] levels > 3x the upper limit of normal (ULN) occurred in 2.3% of women receiving VEOZAH and 0.9% of women receiving placebo in three clinical trials. No serum elevations in total bilirubin (> 2x ULN) occurred. Women with ALT or AST elevations were generally asymptomatic. Transaminase levels returned to pretreatment levels (or close to these) without sequelae with dose continuation, and upon dose interruption, or discontinuation. Women with cirrhosis were not studied.

Perform baseline bloodwork to evaluate for hepatic function and injury prior to VEOZAH initiation. Do not start VEOZAH if concentration of ALT or AST is ≥ 2x ULN or if the total bilirubin is elevated (e.g., ≥ 2x ULN) for the evaluating laboratory. If baseline hepatic transaminase evaluation is < 2x ULN and the total bilirubin is normal, VEOZAH can be started. Perform follow-up evaluations of hepatic transaminase concentration at 3 months, 6 months, and 9 months after initiation of therapy and when symptoms (such as nausea, vomiting, or yellowing of the skin or eyes) suggest liver injury.

ADVERSE REACTIONS

The most common adverse reactions with VEOZAH ≥ 2% and > placebo (VEOZAH % vs. placebo %) are: abdominal pain (4.3% vs. 2.1%), diarrhea (3.9% vs. 2.6%), insomnia (3.9% vs. 1.8%), back pain (3.0% vs. 2.1%), hot flush (2.5% vs. 1.6%), and hepatic transaminase elevation (2.3% vs. 0.8%).

Please click here for full Prescribing Information for VEOZAH® (fezolinetant).